BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients

1. BeOne released positive Phase 1/2 results for sonrotoclax in MCL patients. 2. Study met primary overall response rate endpoint; results promising across secondary measures. 3. FDA approval submission planned for sonrotoclax; applications under review in China. 4. Sonrotoclax has Orphan Drug Designation for MCL, indicating potential market exclusivity. 5. ONC stock increased by 4.46% following the positive news.